DRESDEN, Germany--(BUSINESS WIRE)--Cenix BioScience GmbH, a leading RNA interference (RNAi)-focused contract research organization, today announced that they have signed a new multi-project research agreement with AstraZeneca, thereby expanding their relationship beyond its initial oncology focus, to now include respiratory and inflammation-related indications.
